464 related articles for article (PubMed ID: 23598407)
1. Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.
Brito V; Puigdellívol M; Giralt A; del Toro D; Alberch J; Ginés S
Cell Death Dis; 2013 Apr; 4(4):e595. PubMed ID: 23598407
[TBL] [Abstract][Full Text] [Related]
2. Early Downregulation of p75
Suelves N; Miguez A; López-Benito S; Barriga GG; Giralt A; Alvarez-Periel E; Arévalo JC; Alberch J; Ginés S; Brito V
Mol Neurobiol; 2019 Feb; 56(2):935-953. PubMed ID: 29804232
[TBL] [Abstract][Full Text] [Related]
3. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
Ma Q; Yang J; Li T; Milner TA; Hempstead BL
Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of BDNF and Full-Length TrkB Receptor Ameliorate Striatal Neural Survival in Huntington's Disease.
Silva A; Naia L; Dominguez A; Ribeiro M; Rodrigues J; Vieira OV; Lessmann V; Rego AC
Neurodegener Dis; 2015; 15(4):207-18. PubMed ID: 25896770
[TBL] [Abstract][Full Text] [Related]
5. Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites.
Liot G; Zala D; Pla P; Mottet G; Piel M; Saudou F
J Neurosci; 2013 Apr; 33(15):6298-309. PubMed ID: 23575829
[TBL] [Abstract][Full Text] [Related]
6. The p75 neurotrophin receptor augments survival signaling in the striatum of pre-symptomatic Q175(WT/HD) mice.
Wehner AB; Milen AM; Albin RL; Pierchala BA
Neuroscience; 2016 Jun; 324():297-306. PubMed ID: 26947127
[TBL] [Abstract][Full Text] [Related]
7. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
[TBL] [Abstract][Full Text] [Related]
8. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.
Simmons DA; Belichenko NP; Yang T; Condon C; Monbureau M; Shamloo M; Jing D; Massa SM; Longo FM
J Neurosci; 2013 Nov; 33(48):18712-27. PubMed ID: 24285878
[TBL] [Abstract][Full Text] [Related]
9. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease.
Zuccato C; Marullo M; Conforti P; MacDonald ME; Tartari M; Cattaneo E
Brain Pathol; 2008 Apr; 18(2):225-38. PubMed ID: 18093249
[TBL] [Abstract][Full Text] [Related]
10. 7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington's disease mouse model through specific activation of the PLCγ1 pathway.
García-Díaz Barriga G; Giralt A; Anglada-Huguet M; Gaja-Capdevila N; Orlandi JG; Soriano J; Canals JM; Alberch J
Hum Mol Genet; 2017 Aug; 26(16):3144-3160. PubMed ID: 28541476
[TBL] [Abstract][Full Text] [Related]
11. Impaired TrkB-mediated ERK1/2 activation in huntington disease knock-in striatal cells involves reduced p52/p46 Shc expression.
Ginés S; Paoletti P; Alberch J
J Biol Chem; 2010 Jul; 285(28):21537-48. PubMed ID: 20442398
[TBL] [Abstract][Full Text] [Related]
12. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation.
Miguez A; García-Díaz Barriga G; Brito V; Straccia M; Giralt A; Ginés S; Canals JM; Alberch J
Hum Mol Genet; 2015 Sep; 24(17):4958-70. PubMed ID: 26063761
[TBL] [Abstract][Full Text] [Related]
13. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
[TBL] [Abstract][Full Text] [Related]
14. Brain-derived neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and can be targeted to inhibit tumor cell survival.
Vanhecke E; Adriaenssens E; Verbeke S; Meignan S; Germain E; Berteaux N; Nurcombe V; Le Bourhis X; Hondermarck H
Clin Cancer Res; 2011 Apr; 17(7):1741-52. PubMed ID: 21350004
[TBL] [Abstract][Full Text] [Related]
15. PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.
Saavedra A; García-Martínez JM; Xifró X; Giralt A; Torres-Peraza JF; Canals JM; Díaz-Hernández M; Lucas JJ; Alberch J; Pérez-Navarro E
Cell Death Differ; 2010 Feb; 17(2):324-35. PubMed ID: 19745829
[TBL] [Abstract][Full Text] [Related]
16. Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease.
Pineda JR; Pardo R; Zala D; Yu H; Humbert S; Saudou F
Mol Brain; 2009 Oct; 2():33. PubMed ID: 19860865
[TBL] [Abstract][Full Text] [Related]
17. Brain-derived neurotrophic factor enhances the excitability of rat sensory neurons through activation of the p75 neurotrophin receptor and the sphingomyelin pathway.
Zhang YH; Chi XX; Nicol GD
J Physiol; 2008 Jul; 586(13):3113-27. PubMed ID: 18450779
[TBL] [Abstract][Full Text] [Related]
18. Overcoming the inhibitors of myelin with a novel neurotrophin strategy.
Williams G; Williams EJ; Maison P; Pangalos MN; Walsh FS; Doherty P
J Biol Chem; 2005 Feb; 280(7):5862-9. PubMed ID: 15572360
[TBL] [Abstract][Full Text] [Related]
19. Circadian control of p75 neurotrophin receptor leads to alternate activation of Nrf2 and c-Rel to reset energy metabolism in astrocytes via brain-derived neurotrophic factor.
Ishii T; Warabi E; Mann GE
Free Radic Biol Med; 2018 May; 119():34-44. PubMed ID: 29374533
[TBL] [Abstract][Full Text] [Related]
20. Modulation of Fas-induced apoptosis by p75 neurotrophin receptor in a human neuroblastoma cell line.
Giraud S; Lautrette C; Bessette B; Decourt C; Mathonnet M; Jauberteau MO
Apoptosis; 2005 Dec; 10(6):1271-83. PubMed ID: 16215672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
